Cargando…

The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study

BACKGROUND: Diabetes is a global epidemic affecting approximately 30 million people in the United States. The World Health Organization recommends using technology and telecommunications to improve health care delivery and disease management. The Livongo for Diabetes Program offers a remote monitori...

Descripción completa

Detalles Bibliográficos
Autores principales: Bollyky, Jennifer B, Melton, Stephanie T, Xu, Tong, Painter, Stefanie L, Knox, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803884/
https://www.ncbi.nlm.nih.gov/pubmed/31593545
http://dx.doi.org/10.2196/14799
_version_ 1783461049380372480
author Bollyky, Jennifer B
Melton, Stephanie T
Xu, Tong
Painter, Stefanie L
Knox, Brian
author_facet Bollyky, Jennifer B
Melton, Stephanie T
Xu, Tong
Painter, Stefanie L
Knox, Brian
author_sort Bollyky, Jennifer B
collection PubMed
description BACKGROUND: Diabetes is a global epidemic affecting approximately 30 million people in the United States. The World Health Organization recommends using technology and telecommunications to improve health care delivery and disease management. The Livongo for Diabetes Program offers a remote monitoring technology with Certified Diabetes Educator outreach. OBJECTIVE: The purpose of this study was to examine health outcomes measured by changes in HbA(1c), in time in target blood glucose range, and in depression symptoms for patients enrolled in a remote digital diabetes management program in a Diabetes Center of Excellence setting. METHODS: The impact of the Livongo for Diabetes program on hemoglobin A(1c) (HbA(1c)), blood glucose ranges, and depression screening survey results (Patient Health Questionnaire-2 [PHQ-2]) were assessed over 12 months in a prospective cohort recruited from the University of South Florida Health Diabetes Home for Healthy Living. Any patient ≥18 years old with a diagnosis of diabetes was approached for voluntary inclusion into the program. The analysis was a pre-post design for those members enrolled in the study. Data was collected at outpatient clinic visits and remotely through the Livongo glucose meter. RESULTS: A total of 86 adults were enrolled into the Livongo for Diabetes program, with 49% (42/86) female, an average age of 50 (SD 15) years, 56% (48/86) with type 2 diabetes mellitus, and 69% (59/86) with insulin use. The mean HbA(1c) drop amongst the group was 0.66% (P=.17), with all participants showing a decline in HbA(1c) at 12 months. A 17% decrease of blood glucose checks <70 mg/dL occurred concurrently. Participants with type 2 diabetes not using insulin had blood glucose values within target range (70-180 mg/dL) 89% of the time. Participants with type 2 diabetes using insulin were in target range 68% of the time, and type 1 diabetes 58% of the time. Average PHQ-2 scores decreased by 0.56 points during the study period. CONCLUSIONS: Participants provided with a cellular-enabled blood glucose meter with real-time feedback and access to coaching from a certified diabetes educator in an outpatient clinical setting experienced improved mean glucose values and fewer episodes of hypoglycemia relative to the start of the program.
format Online
Article
Text
id pubmed-6803884
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-68038842019-11-18 The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study Bollyky, Jennifer B Melton, Stephanie T Xu, Tong Painter, Stefanie L Knox, Brian JMIR Diabetes Original Paper BACKGROUND: Diabetes is a global epidemic affecting approximately 30 million people in the United States. The World Health Organization recommends using technology and telecommunications to improve health care delivery and disease management. The Livongo for Diabetes Program offers a remote monitoring technology with Certified Diabetes Educator outreach. OBJECTIVE: The purpose of this study was to examine health outcomes measured by changes in HbA(1c), in time in target blood glucose range, and in depression symptoms for patients enrolled in a remote digital diabetes management program in a Diabetes Center of Excellence setting. METHODS: The impact of the Livongo for Diabetes program on hemoglobin A(1c) (HbA(1c)), blood glucose ranges, and depression screening survey results (Patient Health Questionnaire-2 [PHQ-2]) were assessed over 12 months in a prospective cohort recruited from the University of South Florida Health Diabetes Home for Healthy Living. Any patient ≥18 years old with a diagnosis of diabetes was approached for voluntary inclusion into the program. The analysis was a pre-post design for those members enrolled in the study. Data was collected at outpatient clinic visits and remotely through the Livongo glucose meter. RESULTS: A total of 86 adults were enrolled into the Livongo for Diabetes program, with 49% (42/86) female, an average age of 50 (SD 15) years, 56% (48/86) with type 2 diabetes mellitus, and 69% (59/86) with insulin use. The mean HbA(1c) drop amongst the group was 0.66% (P=.17), with all participants showing a decline in HbA(1c) at 12 months. A 17% decrease of blood glucose checks <70 mg/dL occurred concurrently. Participants with type 2 diabetes not using insulin had blood glucose values within target range (70-180 mg/dL) 89% of the time. Participants with type 2 diabetes using insulin were in target range 68% of the time, and type 1 diabetes 58% of the time. Average PHQ-2 scores decreased by 0.56 points during the study period. CONCLUSIONS: Participants provided with a cellular-enabled blood glucose meter with real-time feedback and access to coaching from a certified diabetes educator in an outpatient clinical setting experienced improved mean glucose values and fewer episodes of hypoglycemia relative to the start of the program. JMIR Publications 2019-10-07 /pmc/articles/PMC6803884/ /pubmed/31593545 http://dx.doi.org/10.2196/14799 Text en ©Jennifer B Bollyky, Stephanie T Melton, Tong Xu, Stefanie L Painter, Brian Knox. Originally published in JMIR Diabetes (http://diabetes.jmir.org), 07.10.2019 https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Diabetes, is properly cited. The complete bibliographic information, a link to the original publication on http://diabetes.jmir.org/, as well as this copyright and license information must be included.
spellingShingle Original Paper
Bollyky, Jennifer B
Melton, Stephanie T
Xu, Tong
Painter, Stefanie L
Knox, Brian
The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study
title The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study
title_full The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study
title_fullStr The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study
title_full_unstemmed The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study
title_short The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study
title_sort effect of a cellular-enabled glucose meter on glucose control for patients with diabetes: prospective pre-post study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803884/
https://www.ncbi.nlm.nih.gov/pubmed/31593545
http://dx.doi.org/10.2196/14799
work_keys_str_mv AT bollykyjenniferb theeffectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy
AT meltonstephaniet theeffectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy
AT xutong theeffectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy
AT painterstefaniel theeffectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy
AT knoxbrian theeffectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy
AT bollykyjenniferb effectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy
AT meltonstephaniet effectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy
AT xutong effectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy
AT painterstefaniel effectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy
AT knoxbrian effectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy